Form 4: Baker Bros. Advisors Report Beneficial Ownership Changes in IGM Biosciences

Baker Bros. Advisors LP reports acquisition of restricted stock units in IGM Biosciences on behalf of affiliated funds due to director retainer fees.

Summary

• Baker Bros. Advisors LP, along with related entities and individuals, filed a Form 4 detailing changes in beneficial ownership of IGM Biosciences, Inc. (IGMS) stock.
• The report indicates the acquisition of 1,994 restricted stock units (RSUs) by Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, in lieu of director retainer fees of $11,500.
• These RSUs are fully vested and were issued under IGM Biosciences' Outside Director Compensation Policy.
• The filing also covers the indirect beneficial ownership of common stock held by 667, L.P. and Baker Brothers Life Sciences, L.P., funds managed by Baker Bros. Advisors LP.
• After the reported transaction, Baker Bros. entities hold 349,160 shares for 667, L.P. and 3,755,474 shares for Baker Brothers Life Sciences, L.P.
• Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the common stock held by these funds due to their ownership interest in the general partners of the funds.
• The filing clarifies the relationships between the various Baker Bros. entities and their roles in managing and advising the funds, emphasizing the disclaimer of beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, indicating standard business operations and insider activity. The sentiment is neutral to slightly positive due to the continued investment by a major shareholder.

Positives

• The acquisition of RSUs reflects ongoing director compensation and alignment with company interests.
• The significant holdings of IGM Biosciences stock by Baker Bros. affiliated funds demonstrate a substantial investment and confidence in the company.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Director compensation in the form of stock and options is a common practice in the biotech industry, aligning director interests with shareholder value.
• Baker Bros. Advisors is a well-known investment firm specializing in biotech, and their holdings in IGM Biosciences are consistent with their investment strategy.
• Comparing the director compensation structure and equity holdings with those of peer companies like Regeneron, Amgen, or Biogen would provide a benchmark for assessing the competitiveness and alignment of incentives at IGM Biosciences.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider ownership and compensation.
• The continued investment by Baker Bros. may signal confidence in the company's prospects.

Key Dates